Literature DB >> 17872362

alpha-Synuclein and Parkinson disease susceptibility.

S Winkler1, J Hagenah, S Lincoln, M Heckman, K Haugarvoll, K Lohmann-Hedrich, V Kostic, M Farrer, C Klein.   

Abstract

BACKGROUND: Mutations in the alpha-synuclein (SNCA) gene have been shown to be responsible for a rare familial form of Parkinson disease (PD). Furthermore, polymorphic variants in multiple regions of the gene have been associated with susceptibility to idiopathic PD in different populations.
OBJECTIVE: To evaluate and to confirm the role of SNCA variants in PD pathogenesis.
METHODS: We included 667 subjects (397 cases with idiopathic PD and 270 healthy, ethnically matched controls) of Northern Central and Southeastern European origin. We analyzed genotypes at 14 markers spanning the SNCA locus and its major haplotype blocks and conducted a haplotype analysis for four promoter markers including the microsatellite marker Rep1.
RESULTS: The three single nucleotide polymorphisms (SNPs) of the promoter region (rs2583988, rs2619364, rs2619363) and a SNP in the 3'UTR (rs356165) of the SNCA gene showed the greatest evidence for an association with PD (p <or= 0.003), with significant pairwise values for linkage disequilibrium (D' >or= 0.74, r (2) >or= 0.29). The promoter haplotype "261-T-G-T" (Rep1-rs2583988-rs2619364-rs2619363) was associated with disease (p = 0.032). The most significant association with PD was generated by excluding Rep1 (p = 0.008). This association remained significant when analyzing the Serbian patients separately and was of borderline significance for the German patients.
CONCLUSIONS: Our findings confirm that genetic variability within the SNCA locus is associated with susceptibility to idiopathic Parkinson disease (PD). We found evidence for disease association with single nucleotide polymorphisms at both the 5' and the 3' end of the gene with pairwise linkage disequilibrium between them. The association was independent of the Rep1 status, and one major SNCA promoter haplotype class seems to be associated with PD susceptibility.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17872362     DOI: 10.1212/01.wnl.0000275524.15125.f4

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  56 in total

1.  Reply to: SNCA variants are associated with increased risk of multiple system atrophy.

Authors:  Owen A Ross; Carles Vilariño-Güell; Zbigniew K Wszolek; Matthew J Farrer; Dennis W Dickson
Journal:  Ann Neurol       Date:  2010-03       Impact factor: 10.422

2.  SNCA variant associated with Parkinson disease and plasma alpha-synuclein level.

Authors:  Ignacio F Mata; Min Shi; Pinky Agarwal; Kathryn A Chung; Karen L Edwards; Stewart A Factor; Douglas R Galasko; Carmen Ginghina; Alida Griffith; Donald S Higgins; Denise M Kay; Hojoong Kim; James B Leverenz; Joseph F Quinn; John W Roberts; Ali Samii; Katherine W Snapinn; Debby W Tsuang; Dora Yearout; Jing Zhang; Haydeh Payami; Cyrus P Zabetian
Journal:  Arch Neurol       Date:  2010-11

3.  Variants in the 3'UTR of SNCA do not affect miRNA-433 binding and alpha-synuclein expression.

Authors:  Ina Schmitt; Ullrich Wüllner; Jan Pierre van Rooyen; Hassan Khazneh; Julian Becker; Alexander Volk; Christian Kubisch; Tim Becker; Vladimir S Kostic; Christine Klein; Alfredo Ramirez
Journal:  Eur J Hum Genet       Date:  2012-05-23       Impact factor: 4.246

4.  The effect of SNCA 3' region on the levels of SNCA-112 splicing variant.

Authors:  Jeanette J McCarthy; Colton Linnertz; Laura Saucier; James R Burke; Christine M Hulette; Kathleen A Welsh-Bohmer; Ornit Chiba-Falek
Journal:  Neurogenetics       Date:  2010-11-03       Impact factor: 2.660

Review 5.  Structural variants in SNCA gene and the implication to synucleinopathies.

Authors:  Ornit Chiba-Falek
Journal:  Curr Opin Genet Dev       Date:  2017-03-02       Impact factor: 5.578

Review 6.  Circadian dysfunction may be a key component of the non-motor symptoms of Parkinson's disease: insights from a transgenic mouse model.

Authors:  L David Willison; Takashi Kudo; Dawn H Loh; Dika Kuljis; Christopher S Colwell
Journal:  Exp Neurol       Date:  2013-01-24       Impact factor: 5.330

7.  The genetic contributions of SNCA and LRRK2 genes to Lewy Body pathology in Alzheimer's disease.

Authors:  Colton Linnertz; Michael W Lutz; John F Ervin; Jawara Allen; Natalie R Miller; Kathleen A Welsh-Bohmer; Allen D Roses; Ornit Chiba-Falek
Journal:  Hum Mol Genet       Date:  2014-04-28       Impact factor: 6.150

8.  Expansion of the Parkinson disease-associated SNCA-Rep1 allele upregulates human alpha-synuclein in transgenic mouse brain.

Authors:  Kenneth D Cronin; Dongliang Ge; Paul Manninger; Colton Linnertz; Anna Rossoshek; Bonnie M Orrison; David J Bernard; Omar M A El-Agnaf; Michael G Schlossmacher; Robert L Nussbaum; Ornit Chiba-Falek
Journal:  Hum Mol Genet       Date:  2009-06-04       Impact factor: 6.150

9.  The therapeutic potential of LRRK2 and alpha-synuclein in Parkinson's disease.

Authors:  Saurabh Sen; Andrew B West
Journal:  Antioxid Redox Signal       Date:  2009-09       Impact factor: 8.401

10.  Genetic regulation of alpha-synuclein mRNA expression in various human brain tissues.

Authors:  Colton Linnertz; Laura Saucier; Dongliang Ge; Kenneth D Cronin; James R Burke; Jeffrey N Browndyke; Christine M Hulette; Kathleen A Welsh-Bohmer; Ornit Chiba-Falek
Journal:  PLoS One       Date:  2009-10-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.